🚀 VC round data is live in beta, check it out!
Lexeo Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lexeo Therapeutics and similar public comparables like Altimmune, Opthea, Prothena Corp., ADC Therapeutics and more.
Lexeo Therapeutics Overview
About Lexeo Therapeutics
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Founded
2017
HQ
Employees
72
Website
Financials (LTM)
EV
$410M
Lexeo Therapeutics Financials
Lexeo Therapeutics reported last 12-month revenue of — and negative EBITDA of ($112M).
In the same LTM period, Lexeo Therapeutics generated — in gross profit, ($112M) in EBITDA losses, and had net loss of ($104M).
Revenue (LTM)
Lexeo Therapeutics P&L
In the most recent fiscal year, Lexeo Therapeutics reported revenue of — and EBITDA of ($96M).
Lexeo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($112M) | XXX | ($96M) | XXX | XXX | XXX |
| Net Profit | ($104M) | XXX | ($98M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lexeo Therapeutics Stock Performance
Lexeo Therapeutics has current market cap of $524M, and enterprise value of $410M.
Market Cap Evolution
Lexeo Therapeutics' stock price is $7.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $410M | $524M | 0.0% | XXX | XXX | XXX | $-1.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLexeo Therapeutics Valuation Multiples
Lexeo Therapeutics trades at (3.7x) EV/EBITDA.
EV / Revenue (LTM)
Lexeo Therapeutics Financial Valuation Multiples
As of March 21, 2026, Lexeo Therapeutics has market cap of $524M and EV of $410M.
Equity research analysts estimate Lexeo Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lexeo Therapeutics has a P/E ratio of (5.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $524M | XXX | $524M | XXX | XXX | XXX |
| EV (current) | $410M | XXX | $410M | XXX | XXX | XXX |
| EV/EBITDA | (3.7x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/EBIT | (3.7x) | XXX | (3.9x) | XXX | XXX | XXX |
| P/E | (5.0x) | XXX | (5.3x) | XXX | XXX | XXX |
| EV/FCF | (4.2x) | XXX | (5.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lexeo Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lexeo Therapeutics Margins & Growth Rates
Lexeo Therapeutics' revenue in the last fiscal year grew by —.
Lexeo Therapeutics' revenue per employee in the last FY averaged $0.0M.
Lexeo Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 11% | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lexeo Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Altimmune | XXX | XXX | XXX | XXX | XXX | XXX |
| Opthea | XXX | XXX | XXX | XXX | XXX | XXX |
| Prothena Corp. | XXX | XXX | XXX | XXX | XXX | XXX |
| ADC Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nxera Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lexeo Therapeutics M&A Activity
Lexeo Therapeutics acquired XXX companies to date.
Last acquisition by Lexeo Therapeutics was on XXXXXXXX, XXXXX. Lexeo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lexeo Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLexeo Therapeutics Investment Activity
Lexeo Therapeutics invested in XXX companies to date.
Lexeo Therapeutics made its latest investment on XXXXXXXX, XXXXX. Lexeo Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lexeo Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lexeo Therapeutics
| When was Lexeo Therapeutics founded? | Lexeo Therapeutics was founded in 2017. |
| Where is Lexeo Therapeutics headquartered? | Lexeo Therapeutics is headquartered in United States. |
| How many employees does Lexeo Therapeutics have? | As of today, Lexeo Therapeutics has over 72 employees. |
| Who is the CEO of Lexeo Therapeutics? | Lexeo Therapeutics' CEO is Richard Nolan Townsend. |
| Is Lexeo Therapeutics publicly listed? | Yes, Lexeo Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Lexeo Therapeutics? | Lexeo Therapeutics trades under LXEO ticker. |
| When did Lexeo Therapeutics go public? | Lexeo Therapeutics went public in 2023. |
| Who are competitors of Lexeo Therapeutics? | Lexeo Therapeutics main competitors are Altimmune, Opthea, Prothena Corp., ADC Therapeutics. |
| What is the current market cap of Lexeo Therapeutics? | Lexeo Therapeutics' current market cap is $524M. |
| Is Lexeo Therapeutics profitable? | No, Lexeo Therapeutics is not profitable. |
| What is the current EBITDA of Lexeo Therapeutics? | Lexeo Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Lexeo Therapeutics? | Current EBITDA multiple of Lexeo Therapeutics is (3.7x). |
| What is the current FCF of Lexeo Therapeutics? | Lexeo Therapeutics' last 12 months FCF is ($97M). |
| What is the current EV/FCF multiple of Lexeo Therapeutics? | Current FCF multiple of Lexeo Therapeutics is (4.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.